Autologous T cell immunotherapy scale out manufacturing models – the biotech perspective

Cell Gene Therapy Insights 2018; 4(11), 1073-1076.


Published: 18 December 2018
Nina Kotsopoulou

DR NINA (Ekaterini) KOTSOPOULOU is Vice President of Process Development at Autolus. She joined the UCL spin-out CAR-T company in 2015 and set-up the vector and CAR-T production process and analytics, including delivery of the first clinical patient batches. Nina has a BSc in Chemistry from the University of Athens and a DPhil in lentiviral vectors for gene therapy from Oxford University. Following her PhD, she briefly worked in her supervisors’ company, Oxford BioMedica, and went on to do 2 post-docs on haematopoietic stem cell biology, at Harvard Medical School and the University of Cambridge. She then joined GSK, where she initially led cell line development and associated process research for monoclonal antibodies and derivatives thereof. She then led Process Development for GSK’s Cell and Gene Therapy portfolio, including working with the inspirational team at TIGET, and completing the MAA submission for the first product, Strimvelis, for the treatment of ADA-SCID.